All Stories

  1. Multivariate Optimization Applied to the Synthesis of Meglumine Antimoniate with Low Levels of Trivalent Antimony
  2. Speciation of Antimony in Injectable Leishmanicidal Drugs by Lowering Citric Acid Concentration Used in Hydride Generation Atomic Absorption Spectrometry Analysis
  3. Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases
  4. Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis
  5. Accelerated Blood Clearance (ABC) Phenomenon Favors the Accumulation of Tartar Emetic in Pegylated Liposomes in BALB/c Mice Liver
  6. Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control
  7. Extracellular Vesicles from Adipose-Derived Mesenchymal Stem/Stromal Cells Accelerate Migration and Activate AKT Pathway in Human Keratinocytes and Fibroblasts Independently of miR-205 Activity
  8. Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells
  9. Injectable Liposomal Formulations: Systematic Analysis for Regulatory Purposes
  10. Silver and Nitrate Oppositely Modulate Antimony Susceptibility through Aquaglyceroporin 1 in Leishmania (Viannia) Species
  11. Oral nanocarrier for leishmaniasis treatment
  12. α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles
  13. Redox-Active Metal Complexes in Trypanosomatids
  14. In vitro antileishmanial activity of Brazilian plant species
  15. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite
  16. Nanoemulsions loaded with amphotericin B: A new approach for the treatment of leishmaniasis
  17. 0109 : Increase liposomes cardioprotective activity of pyridostigmine
  18. Intrachromosomal Amplification, Locus Deletion and Point Mutation in the Aquaglyceroporin AQP1 Gene in Antimony Resistant Leishmania (Viannia) guyanensis
  19. Cardiovascular and behavioral effects produced by administration of liposome-entrapped GABA into the rat central nervous system
  20. Atoxic nanopartilce for leishmaniasis treatment
  21. Nanocarriers for Improved Delivery of Angiotensin-(1-7)
  22. Gadolinium(III) Complexes with N-Alkyl-N-methylglucamine Surfactants Incorporated into Liposomes as Potential MRI Contrast Agents
  23. Association of Liposome-Encapsulated Trivalent Antimonial with Ascorbic Acid: An Effective and Safe Strategy in the Treatment of Experimental Visceral Leishmaniasis
  24. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis
  25. Novel Triphenylantimony(V) and Triphenylbismuth(V) Complexes with Benzoic Acid Derivatives: Structural Characterization, in Vitro Antileishmanial and Antibacterial Activities and Cytotoxicity against Macrophages
  26. Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
  27. Effect of liposome entrapped‐GABA on the expression of nNOS and GABAA receptors in neurons (1130.11)
  28. Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against SbIII-sensitive and -resistant parasites
  29. Antimony transport mechanisms in resistant leishmania parasites
  30. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis
  31. Hepatotoxicity of Pentavalent Antimonial Drug: Possible Role of Residual Sb(III) and Protective Effect of Ascorbic Acid
  32. Relationship between clinical and pathological signs and severity of canine leishmaniasis
  33. Complement activation-related pseudoallergy in dogs following intravenous administration of a liposomal formulation of meglumine antimoniate
  34. Activation of Leishmania spp. leishporin: evidence that dissociation of an inhibitor not only improves its lipid-binding efficiency but also endows it with the ability to form pores
  35. Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis
  36. Development and characterization of multilamellar liposomes containing pyridostigmine
  37. Chemistry of antimony-based drugs in biological systems and studies of their mechanism of action
  38. Unexpectedly high levels of antimony (III) in the pentavalent antimonial drug Glucantime: insights from a new voltammetric approach
  39. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes
  40. Improved Antileishmanial Activity of Dppz through Complexation with Antimony(III) and Bismuth(III): Investigation of the Role of the Metal
  41. Heparan Sulfate Proteoglycan-Mediated Entry Pathway for Charged Tri-Platinum Compounds: Differential Cellular Accumulation Mechanisms for Platinum
  42. Efficacy of Combined Therapy with Liposome-Encapsulated Meglumine Antimoniate and Allopurinol in Treatment of Canine Visceral Leishmaniasis
  43. Greater binding affinity of trivalent antimony to a CCCH zinc finger domain compared to a CCHC domain of kinetoplastid proteins
  44. Antimony(V) and Bismuth(V) Complexes of Lapachol: Synthesis, Crystal Structure and Cytotoxic Activity
  45. Interaction of arsenite with a zinc finger CCHC peptide: Evidence for formation of an As–Zn-peptide mixed complex
  46. Occurrence of anti-Neospora caninum and anti-Toxoplasma gondii antibodies in dogs with visceral leishmaniasis
  47. Gene Expression Profiling and Molecular Characterization of Antimony Resistance in Leishmania amazonensis
  48. Determination of sphingomyelinase-D activity of Loxosceles venoms in sphingomyelin/cholesterol liposomes containing horseradish peroxidase
  49. Liposome-Encapsulated Neuropeptides for Site-Specific Microinjection
  50. Reduced cardiovascular alterations of tartar emetic administered in long-circulating liposomes in rats
  51. New delivery strategies for the old pentavalent antimonial drugs
  52. New insights into the mode of action of ultradeformable vesicles using calcein as hydrophilic fluorescent marker
  53. Prolonged cardioprotective effect of pyridostigmine encapsulated in liposomes
  54. Novel platinum(II) complexes of long chain aliphatic diamine ligands with oxalato as the leaving group: comparative cytotoxic activity relative to chloride precursors
  55. Influence of the nucleobase on the physicochemical characteristics and biological activities of SbV-ribonucleoside complexes
  56. Liposome encapsulation of lipophilic N-alkyl-propanediamine platinum complexes: impact on their cytotoxic activity and influence of the carbon chain length
  57. Membrane binding requirements for the cytolytic activity ofLeishmania amazonensisleishporin
  58. Pentavalent Antimonials: New Perspectives for Old Drugs
  59. Chapter 3 Physicochemical and Pharmacokinetic Characterization of Ultradeformable Vesicles using Calcein as Hydrophilic Fluorescent Marker
  60. Reduced Tissue Parasitic Load and Infectivity to Sand Flies in Dogs Naturally Infected by Leishmania (Leishmania) chagasi following Treatment with a Liposome Formulation of Meglumine Antimoniate
  61. New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate
  62. Interaction of trivalent antimony with a CCHC zinc finger domain: potential relevance to the mechanism of action of antimonial drugs
  63. Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies
  64. Effect of cholesterol on the interaction of the amphibian antimicrobial peptide DD K with liposomes
  65. A novel approach based on nanotechnology for investigating the chronic actions of short-lived peptides in specific sites of the brain
  66. Kinetics of antimony(V) reduction by L-cysteine: pharmacological implications and application to the determination of antimony in pentavalent antimonial drugs
  67. Mode of action of β-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate
  68. Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH
  69. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size
  70. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance
  71. Synthesis and characterization of Sb(V)–adenosine and Sb(V)–guanosine complexes in aqueous solution
  72. Chapter 2 Liposomes as a Tool for the Study of the Chronic Actions of Short-lived Peptides in Specific Sites of the Brain
  73. Angiotensin-(1-7): Blood, Heart, and Blood Vessels
  74. Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio
  75. Pentavalent Antimonials: From Chemistry to the Design of New Drugs
  76. Site-specific microinjection of liposomes into the brain for local infusion of a short-lived peptide
  77. Oral Delivery of Meglumine Antimoniate-β-Cyclodextrin Complex for Treatment of Leishmaniasis
  78. Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes
  79. Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonate
  80. Antimony(V) complex formation with adenine nucleosides in aqueous solution
  81. Long-Lasting Cardiovascular Effects of Liposome-Entrapped Angiotensin-(1-7) at the Rostral Ventrolateral Medulla
  82. Diffusion limited field induced aggregation of magnetic liposomes
  83. P-Glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine
  84. Glutathione-Induced Conversion of Pentavalent Antimony to Trivalent Antimony in Meglumine Antimoniate
  85. P-Glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine
  86. Vertical toxoplasmosis in a murine model. Protection after immunization with antigens of Toxoplasma gondii incorporated into liposomes
  87. SYNTHESIS OF TRIORGANOANTIMONY DERIVATIVES OF QUERCETIN
  88. Long-Lasting Pressor Effect of Liposome-Encapsulated Angiotensin-(1-7) Following Unilateral Microinjection into the Rat Rostral Ventrolateral Medulla
  89. Novel methods for the encapsulation of meglumine antimoniate into liposomes
  90. Protection against Toxoplasmosis in Mice Immunized with Different Antigens of Toxoplasma gondii Incorporated into Liposomes
  91. Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps
  92. Liposomes: from biophysics to the design of peptide vaccines
  93. Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature
  94. The Use of Liposomes as Snake Venom Vehicles. Application in Protective Immunization
  95. Evaluation of the schistosomicidal efficacy of liposome - Entrapped Oxamniquine
  96. Encapsulation of native crotoxin in liposomes: A safe approach for the production of antivenom and vaccination against Crotalus durissus terrificus venom
  97. Analysis of Multidrug Transporter in Living Cells
  98. Novel liposome systems based on the incorporation of (perfluoroalkyl) alkenes (FmHnE) into the bilayer of phospholipid liposomes
  99. Permeability and stability in buffer and in human serum of fluorinated phospholipid-based liposomes
  100. Fluorometric determination in biological fluids of the release kinetics of liposome-entrapped doxorubicin
  101. Incorporation of a perfluoroalkylalkane (RFRH) into the phospholipid bilayer of dmpc liposomes results in greater encapsulation stability
  102. Fluorinated Phospholipid-Based Vesicles as Potential Drug Carriers: Encapsulation/Sustaining of Drugs and Stability in Human Serum
  103. Extended in vivo blood circulation time of fluorinated liposomes
  104. Resistance to Anthracyclines in Multidrug Resistant Cells. Role of the Membrane Transport
  105. DNA-containing liposomes as a model for the study of cell membrane permeation by anthracycline derivatives
  106. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells
  107. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and -sensitive K562 cells
  108. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei
  109. Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration
  110. Membrane-phorbol ester interactions monitored by circular dichroism